
Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model.
Identifying new molecular adjuvants that elicit effective vaccine-induced CD8(+) T cell immunity may be critical for the elimination of many challenging diseases including Tuberculosis, HIV and cancer. Here, we report that co-administration of molecular adjuvant IL-33 during vaccination enhanced the magnitude and function of antigen (Ag)-specific CD8(+) T cells against a model Ag, LCMV NP target protein. These enhanced responses were characterized by higher frequencies of Ag-specific, polyfunctional CD8(+) T cells exhibiting cytotoxic characteristics. Importantly, these cells were capable of robust expansion upon Ag-specific restimulation in vivo and conferred remarkable protection against a high dose lethal LCMV challenge. In addition, we demonstrate the ability of IL-33 to amplifying the frequency of Ag-specific KLRG1(+) effector CD8(+) T cells. These data show that IL-33 is a promising immunoadjuvant at improving T cell immunity in a vaccine setting and suggest further development and understanding of this molecular adjuvant for strategies against many obstinate infectious diseases and cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Virology
- Vaccines, DNA
- Mice, Inbred C57BL
- Lymphocytic choriomeningitis virus
- Interleukin-33
- Immunologic Memory
- Immunity, Cellular
- Disease Models, Animal
- CD8-Positive T-Lymphocytes
- Arenaviridae Infections
Citation

Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Virology
- Vaccines, DNA
- Mice, Inbred C57BL
- Lymphocytic choriomeningitis virus
- Interleukin-33
- Immunologic Memory
- Immunity, Cellular
- Disease Models, Animal
- CD8-Positive T-Lymphocytes
- Arenaviridae Infections